ID,'_thumbnail_id',false); $thumb = wp_get_attachment_image_src($thumb[0], false); $thumb = $thumb[0]; $default_img = get_bloginfo('stylesheet_directory').'/imagenes/imagen_por_defecto.png'; ?> " />
Seleccionar página

Sanofiвђ™s Fda Nod In Hemophilia Gives Patients More Convenience, Brings Roche New Competition Вђ“ Mr Validity 🆕 Full HD

The FDA approved Sanofi’s Altuviiio in February 2023 as a once-weekly factor VIII replacement therapy for hemophilia A, offering sustained, near-normal factor activity levels. Positioned as a direct competitor to Roche’s Hemlibra, the drug aims to reduce injection frequency while providing high efficacy in clinical trials. Read the full story at MedCity News .